Altimmune (ALT) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($264.9 million vs $258.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | VCRE |
|---|---|---|
| Share price | $1.33 | $9.41 |
| Market cap | $258.80M | $264.89M |
| 1-day change | -5.67% | -5.09% |
| YTD return | -63.16% | — |
| 1-year return | -72.35% | — |
| 5-year return | -87.24% | — |
| EPS (TTM) | $-0.71 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.00K | — |
| Revenue growth (YoY) | +105.00% | — |
| Net income (latest FY) | $-88.09M | — |
| Operating margin | -230460.98% | — |
| Net margin | -214860.98% | — |
| 52-week high | $6.44 | $17.80 |
| 52-week low | $1.32 | $7.88 |
| Distance from 52-week high | -79.35% | -47.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1127.82% | +158.90% |
| Average volume | 3.91M | 23.31K |
| Shares outstanding | 194.59M | 28.16M |
| Employees | 57 | 50 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees
ALT vs VCRE FAQ
Which is bigger, Altimmune or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $264.89M compared with $258.80M for Altimmune (ALT).
Are Altimmune and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.